You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
微芯生物(688321.SH):西奧羅尼膠囊一線治療廣泛期小細胞肺癌獲得藥物臨牀試驗批准通知書
格隆匯 11-01 17:26

格隆匯11月1日丨微芯生物(688321.SH)公佈,公司及全資子公司成都微芯藥業有限公司近日收到國家藥品監督管理局簽發的境內生產藥品註冊臨牀試驗的《藥物臨牀試驗批准通知書》,同意公司西奧羅尼膠囊聯合PD-(L)1單抗及化療在廣泛期小細胞肺癌一線治療患者中開展臨牀試驗。

截至本公吿披露日,西奧羅尼在國內已完成單藥治療小細胞肺癌的III期臨牀試驗(針對三線及三線後治療),西奧羅尼聯合化療治療卵巢癌的III期臨牀試驗正在推進中,西奧羅尼單藥或聯合治療三陰性乳腺癌、軟組織肉瘤和胰腺癌的II期臨牀試驗也在推進中。另外,西奧羅尼單藥治療小細胞肺癌/實體瘤的Ib/II期臨牀試驗在美國順利推進中。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account